|
"lu s n"的相关文件
显示项目 111-135 / 140 (共6页)
<< < 1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
| 國立成功大學 |
2021 |
The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study
|
Wu, G.H.-M.;Yang, W.-W.;Liu, C.-L.;Pwu, R.-F.;Chien, R.-N.;Lee, P.-C.;Chen, S.-C.;Chen, D.-S.;Lu, S.-N. |
| 臺大學術典藏 |
2020-12-28T08:14:10Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Yen-Hsuan Ni;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Wang P.-M.; Chao Y.; Chen L.-T.; Hsu C.; Cheng A.-L.; Lin C.-C.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-12-28T08:14:08Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Hu T.-H.; Huang Y.-H.; Chen C.-H.; Liu C.-J.; Peng C.-Y.; Kao J.-H.; Chien R.-N.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2020-12-24T07:20:03Z |
Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study
|
TAI-SHUAN LAI; Lee M.-H.; Yang H.-I.; You S.-L.; Lu S.-N.; Wang L.-Y.; Yuan Y.; L'Italien G.; Chien K.-L.; Chen C.-J.; for the REVEAL-HCV Study Group |
| 臺大學術典藏 |
2020-11-27T03:28:43Z |
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study
|
Chen T.H.H.; Sun C.A.; Wu M.H.; Chen S.Y.; Chu K.E.; Ho S.C.; Lu T.G.; Wu W.P.; Ou T.Y.; Lin C.G.; Shih K.C.; Chung W.S.; Li C.; CHIEH-CHANG CHEN; How W.C.; Lee M.-H.; Yang H.-I.; Lu S.-N.; Jen C.-L.; You S.-L.; Wang L.-Y.; Wang C.-H.; Chen W.J.; Chen C.-J.; Hsieh C.Y.; Lee H.S.; Yang P.M.; Chen C.H.; Chen J.D.; Huang S.P.; Jan C.F. |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2020-08-11T08:36:42Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Po-Chin Liang;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Huo T.-I.; Liao L.-Y.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Lu S.-N. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Huang Y.-H.; Lee K.-T.; Wang C.-C.; Chau G.-Y.; Lee W.-C.; Ting C.-T.; Lee P.-H.; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Chia-Hsien Cheng;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-02-19T09:33:41Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ming-Chih Ho;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group;Surveillance Group;Diagnosis Group;Staging Group;Surgery Group;Tace/Tare/Hai Group;Target Therapy/Systemic Therapy Group;Radiotherapy Group;Prevention Group;Drafting Group; Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; MING-CHIH HO; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group |
| 臺大學術典藏 |
2020-02-10T08:59:32Z |
Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan
|
Chen T.H.-H.;Chen C.-J.;Yen M.-F.;Lu S.-N.;Sun C.-A.;Huang G.-T.;Yang P.-M.;Lee H.-S.;Duffy S.W.; Chen T.H.-H.; Chen C.-J.; Yen M.-F.; Lu S.-N.; Sun C.-A.; Huang G.-T.; Yang P.-M.; Lee H.-S.; Duffy S.W.; HSUAN-SHU LEE |
| 臺大學術典藏 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; CHIH-HUNG HSU; Yen Y.; Tabernero J.; Shen Y.-C.; Hsu C.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Cheng A.-L.; Martinelli E.; Chen L.-T.; Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Hsu C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chih-Hung Hsu;Yoshino T.;Douillard J.-Y.; Choo S.P.; Ho G.F.; Lim H.-Y.; Ikeda M.; Bhattacharyya G.S.; Qin S.; Pentheroudakis G. |
| 國立成功大學 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, L.-T.;Martinelli, E.;Cheng, A.-L.;Pentheroudakis, G.;Qin, S.;Bhattacharyya, G.S.;Ikeda, M.;Lim, H.-Y.;Ho, G.F.;Choo, S.P.;Ren, Z.;Malhotra, H.;Ueno, M.;Ryoo, B.-Y.;Kiang, T.C.;Tai, D.;Vogel, A.;Cervantes, A.;Lu, S.-N.;Yen, C.-J.;Huang, Y.-H.;Chen, S.-C.;Hsu, C.;Shen, Y.-C.;Tabernero, J.;Yen, Yen Y.;Hsu, C.-H.;Yoshino, T.;Douillard, J.-Y. |
| 臺大學術典藏 |
2018-09-10T18:06:03Z |
Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study
|
Lai, T.-S. ; Lee, M.-H. ; Yang, H.-I. ; You, S.-L. ; Lu, S.-N. ; Wang, L.-Y. ; Yuan, Y. ; L'Italien, G. ; Chien, K.-L. ; Chen, C.-J.; TAI-SHUAN LAI; KUO-LIONG CHIEN |
| 臺大學術典藏 |
2018-09-10T18:06:03Z |
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease
|
Lai, T.-S. ; Lee, M.-H. ; Yang, H.-I. ; You, S.-L. ; Lu, S.-N. ; Wang, L.-Y. ; Yuan, Y. ; L'Italien, G. ; Chien, K.-L. ; Chen, C.-J.; TAI-SHUAN LAI; KUO-LIONG CHIEN |
| 臺大學術典藏 |
2018-09-10T18:02:16Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee, M.-H.;Huang, C.-F.;Lai, H.-C.;Lin, C.-Y.;Dai, C.-Y.;Liu, C.-J.;Wang, J.-H.;Huang, J.-F.;Su, W.-P.;Yang, H.-C.;Kee, K.-M.;Yeh, M.-L.;Chuang, P.-H.;Hsu, S.-J.;Huang, C.-I.;Kao, J.-T.;Chen, C.-C.;Chen, S.-H.;Jeng, W.-J.;Yang, H.-I.;Yuan, Y.;Lu, S.-N.;Sheen, I.-S.;Liu, C.-H.;Peng, C.-Y.;Kao, J.-H.;Yu, M.-L.;Chuang, W.-L.;Chen, C.-J.; HUNG-CHIH YANG; CHUN-JEN LIU; CHEN-HUA LIU; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T15:17:28Z |
A polymorphism in interferon L3 Is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis c virus infection
|
Chang, K.-C. ; Tseng, P.-L. ; Wu, Y.-Y. ; Hung, H.-C. ; Huang, C.-M. ; Lu, S.-N. ; Wang, J.-H. ; Lee, C.-M. ; Chen, C.-H. ; Tsai, M.-C. ; Yen, Y.-H. ; Lin, M.-T. ; Wu, C.-K. ; Huang, C.-C. ; Chen, H.-H. ; Hu, T.-H.; HSIU-HSI CHEN |
| 臺大學術典藏 |
2018-09-10T14:59:09Z |
Distinct seromarkers predict different milestones of chronic hepatitis B progression
|
Liu, J. ; Yang, H.-I. ; Lee, M.-H. ; Batrla-Utermann, R. ; Jen, C.-L. ; Lu, S.-N. ; Wang, L.-Y. ; You, S.-L. ; Hsiao, C.K. ; Chen, C.-J.; CHUHSING KATE HSIAO |
| 臺大學術典藏 |
2018-09-10T09:41:04Z |
Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy
|
Chang, K-C;Wu, Y-Y;Hung, C-H;Lu, S-N;Lee, C-M;Chiu, K-W;Tsai, M-C;Tseng, P-L;Huang, C-M;Cho, C-L;Chen, H-H;Hu, T-H; HSIU-HSI CHEN; Chang, K-C; Wu, Y-Y; Hung, C-H; Lu, S-N; Lee, C-M; Chiu, K-W; Tsai, M-C; Tseng, P-L; Huang, C-M; Cho, C-L; Chen, H-H; Hu, T-H |
| 臺大學術典藏 |
2018-09-10T08:44:32Z |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
|
Yeh, M.-L.; Hung, C.-H.; Huang, J.-F.; Liu, C.-J.; Lee, C.-M.; Dai, C.-Y.; Wang, J.-H.; Lin, Z.-Y.; Lu, S.-N.; Hu, T.-H.; Yu, M.-L.; Kao, J.-H.; Chuang, W.-L.; Chen, P.-J.; Chen, D.-S.; CHUN-JEN LIU; PEI-JER CHEN; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T04:06:00Z |
Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan
|
Chen, T.H.-H.;Chen, C.-J.;Yen, M.-F.;Lu, S.-N.;Sun, C.-A.;Huang, G.-T.;Yang, P.-M.;Lee, H.-S.;Duffy, S.W.; Chen, T.H.-H.; Chen, C.-J.; Yen, M.-F.; Lu, S.-N.; Sun, C.-A.; Huang, G.-T.; Yang, P.-M.; Lee, H.-S.; Duffy, S.W.; HSUAN-SHU LEE; HSIU-HSI CHEN; GUAN-TARN HUANG; PEI-MING YANG |
| 臺大學術典藏 |
2018 |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Chiun Hsu;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Chiun Hsu; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2018 |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
PO-HUANG LEE; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Po-Huang Lee;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國立成功大學 |
2018 |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu, S.-N.;Wang, J.-H.;Su, C.-W.;Wang, T.-E.;Dai, C.-Y.;Chen, Chen C.-H.;Chen, R.-C.;Yang, S.-S.;Hung, C.-F.;Huang, S.-F.;Liao, Liao L.-Y.;Huo, T.-I.;Wu, C.-C.;Lee, P.-H.;Ting, C.-T.;Lee, W.-C.;Chau, G.-Y.;Wang, C.-C.;Lee, K.-T.;Huang, Y.-H.;Ho, M.-C.;Lin, S.-M.;Huang, G.-T.;Chen, K.-Y.;Lin, X.-Z.;Hwang, J.-I.;Chiou, Y.-Y.;Wang, C.-K.;Hu, J.-T.;Chen, S.-C.;Liang, P.-C.;Lee, R.-C.;Wu, D.-K.;Lin, C.-Y.;Lin, C.-C.;Cheng, A.-L.;Hsu, C.;Chao, Y.;Chen, L.-T.;Wang, P.-M.;Wang, P.-M.;Hong, J.-H.;Hsu, Hsu H.-C.;Chen, S.-W.;Leung, S.W.;Cheng, J.C.-H.;Wu, J.-C.;Wu, C.-Y.;Hsu, Y.-C.;Hsu, C.-W.;Ni, Y.-H.;Lin, C.-L.;group, Local ablation;group, Surveillance;group, Diagnosis;group, Staging;group, Surgery;group, TACE/TARE/HAI;group, Target therapy/systemic therapy;group, Radiotherapy;group, Prevention;group, Drafting |
| 臺大學術典藏 |
2017 |
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease
|
TAI-SHUAN LAI; Lee M.-H.; Yang H.-I.; You S.-L.; Lu S.-N.; Wang L.-Y.; Yuan Y.; L'Italien G.; Chien K.-L.; Chen C.-J.; REVEAL-HCV Study Group |
显示项目 111-135 / 140 (共6页)
<< < 1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
|
